EYEGATE PHARMACEUTICALS INC Contracts & Agreements
114 Contracts & Agreements
- Business Finance (61 contracts)
- Business Operations (2)
- Human Resources (18)
- Intellectual Property (8)
- Uncategorized (25)
- First Amendment to Intellectual Property License Agreement, dated as of June 12, 2023, between Kiora Pharmaceuticals, Inc. and Sentrx Animal Care, Inc (Filed With SEC on June 15, 2023)
- Exclusive License Agreement, dated as of June 12, 2023, between Kiora Pharmaceuticals, Inc. and Sentrx Animal Care, Inc (Filed With SEC on June 15, 2023)
- Underwriting Agreement dated as of June 2, 2023, by and between Kiora Pharmaceuticals, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on June 6, 2023)
- Warrant Agency Agreement dated June (Filed With SEC on June 6, 2023)
- Form of Underwriting Agreement between the Registrant and Ladenburg Thalmann & Co. Inc (Filed With SEC on June 1, 2023)
- Form of Class C Common Stock Purchase Warrant (Filed With SEC on June 1, 2023)
- Form of Class D Common Stock Purchase Warrant (Filed With SEC on June 1, 2023)
- Form of Warrant Agency Agreement by and between the Registrant and VStock Transfer, LLC (Filed With SEC on June 1, 2023)
- Form of Underwriting Agreement between the Registrant and Ladenburg Thalmann & Co. Inc (Filed With SEC on May 12, 2023)
- Form of Common Stock Purchase Warrant (Filed With SEC on May 12, 2023)
- Form of Warrant Agency Agreement by and between the Registrant and VStock Transfer, LLC (Filed With SEC on May 12, 2023)
- Form of Warrant (Filed With SEC on February 3, 2023)
- Securities Purchase Agreement, dated as of February 2, 2023, by and between Kiora Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on February 3, 2023)
- Registration Rights Agreement, dated as of February 2, 2023, by and between Kiora Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on February 3, 2023)
- Purchase Agreement, dated as of February 3, 2023, by and between Kiora Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on February 3, 2023)
- Registration Rights Agreement, dated as of February 3, 2023, by and between Kiora Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on February 3, 2023)
- Form of Inducement Warrant (Filed With SEC on November 21, 2022)
- Form of Inducement Letter (Filed With SEC on November 21, 2022)
- Offer Letter by and between Kiora Pharmaceuticals, Inc. and Melissa Tosca, dated as of August 18, 2022 (Filed With SEC on September 16, 2022)
- Underwriting Agreement dated as of July 22, 2022, by and between Kiora Pharmaceuticals, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on July 26, 2022)
- Warrant Agency Agreement dated July 22, 2022, by and between Kiora Pharmaceuticals, Inc. and VStock Transfer, LLC (Filed With SEC on July 26, 2022)
- Form of Underwriting Agreement between the Registrant and Ladenburg Thalmann & Co. Inc (Filed With SEC on July 21, 2022)
- Form of Class A Warrant (Filed With SEC on July 21, 2022)
- Form of Class B Warrant (Filed With SEC on July 21, 2022)
- Form of Warrant Agency Agreement by and between the Registrant and VStock Transfer, LLC (Filed With SEC on July 21, 2022)
- Form of Underwriting Agreement between the Registrant and Ladenburg Thalmann & Co. Inc (Filed With SEC on July 19, 2022)
- Form of Common Stock Purchase Warrant (Filed With SEC on July 19, 2022)
- Form of Underwriting Agreement between the Registrant and Ladenburg Thalmann & Co. Inc (Filed With SEC on July 13, 2022)
- Form of Common Stock Purchase Warrant (Filed With SEC on July 13, 2022)
- Form of Warrant Agency Agreement by and between the Registrant and VStock Transfer, LLC (Filed With SEC on July 13, 2022)
- Consulting Agreement, dated as of March 9, 2022, between Danforth Advisors, LLC and the Company (Filed With SEC on April 26, 2022)
- Separation Agreement by and between Kiora Pharmaceuticals, Inc. and Stephen From, dated January 31, 2022 (Filed With SEC on February 1, 2022)
- Stock Purchase Agreement, dated as of October 21, 2021, by and among EyeGate Pharmaceuticals, Inc. and the Sellers listed therein (Filed With SEC on October 26, 2021)
- Employment Agreement by and between EyeGate Pharmaceuticals, Inc., Bayon Therapeutics Pty Ltd and Eric J. Daniels, dated as of October 21, 2021 (Filed With SEC on October 26, 2021)
- EyeGate Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended (Filed With SEC on August 12, 2021)
- Form of Warrant (Filed With SEC on August 10, 2021)
- Form of Placement Agent Warrant (Filed With SEC on August 10, 2021)
- Form of Securities Purchase Agreement (Filed With SEC on August 10, 2021)
- Engagement Letter between EyeGate Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC, dated as of August 5, 2021 (Filed With SEC on August 10, 2021)
- Employment Agreement by and between EyeGate Pharmaceuticals, Inc. and Brian M. Strem, dated as of July 22, 2021 (Filed With SEC on July 26, 2021)
- Patent and Know How Assignment Agreement, dated as of July 2, 2013, by and between Panoptes Pharma Ges.m.b.H and 4SC Discovery GmbH (Filed With SEC on March 25, 2021)
- Patent License Agreement, dated as of July 2, 2013, by and between Panoptes Pharma Ges.m.b.H. and 4SC Discovery GmbH (Filed With SEC on March 25, 2021)
- Managing Director Service Agreement by and between Panoptes Pharma Ges.m.b.H and Dr. Franz Obermayr, dated as of December 18, 2020 (Filed With SEC on February 1, 2021)
- First Amendment to Managing Director Service Agreement by and among Panoptes Pharma Ges.m.b.H, EyeGate Pharmaceuticals, Inc. and Dr. Franz Obermayr, dated as of January 29, 2021 (Filed With SEC on February 1, 2021)
- Fourth Amended and Restated Employment Agreement by and between EyeGate Pharmaceuticals, Inc. and Stephen From, dated as of January 29, 2021 (Filed With SEC on February 1, 2021)
- Form of Warrant (Filed With SEC on January 6, 2021)
- Securities Purchase Agreement between the Company and Armistice Capital Master Fund, Ltd. dated as of January 5, 2021 (Filed With SEC on January 6, 2021)
- Registration Rights Agreement between the Company and Armistice Capital Master Fund, Ltd. dated as of January 5, 2021 (Filed With SEC on January 6, 2021)
- Share Purchase Agreement, dated as of December 18, 2020, by and among EyeGate Pharmaceuticals, Inc. and the Sellers listed therein (Filed With SEC on December 21, 2020)
- Registration Rights Agreement, dated as of December 18, 2020, by and among EyeGate Pharmaceuticals, Inc. and the Sellers listed therein (Filed With SEC on December 21, 2020)
- Employment Agreement by and between EyeGate Pharmaceuticals, Inc. and Sarah Romano, dated as of March 23, 2020 (Filed With SEC on March 24, 2020)
- Description of Securities (Filed With SEC on March 4, 2020)
- Exclusive Sub-License Agreement, dated as of September 12, 2013, by and between Jade Therapeutics, Inc. and Biotime, Inc (Filed With SEC on March 4, 2020)
- Amendment No. 1 to Sub-License Agreement, dated as of September 18, 2015, by and between Jade Therapeutics, Inc. and Biotime, Inc (Filed With SEC on March 4, 2020)
- Amendment No. 2 to Sub-License Agreement, dated as of February 17, 2016, by and between Jade Therapeutics, Inc. and Biotime, Inc (Filed With SEC on March 4, 2020)
- Form of Placement Agent Warrant (Filed With SEC on December 31, 2019)
- Form of Securities Purchase Agreement (Filed With SEC on December 31, 2019)
- Engagement Letter between EyeGate Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC, dated as of December 30, 2019 (Filed With SEC on December 31, 2019)
- EyeGate Pharmaceuticals, Inc. Amended and Restated Change in Control Severance Plan (Filed With SEC on December 3, 2019)
- Amendment to Third Amended and Restated Employment Agreement by and between EyeGate Pharmaceuticals, Inc. and Stephen From, dated as of November 26, 2019 (Filed With SEC on December 3, 2019)
- Form of Warrant (Filed With SEC on September 30, 2019)
- Securities Purchase Agreement between the Company and Armistice Capital Master Fund, Ltd. dated as of September 29, 2019 (Filed With SEC on September 30, 2019)
- Registration Rights Agreement between the Company and Armistice Capital Master Fund, Ltd. dated as of September 29, 2019 (Filed With SEC on September 30, 2019)
- Intellectual Property License Agreement between the Company and SentrX Animal Care, Inc., dated as of September 26, 2018 (Filed With SEC on October 2, 2018)
- EyeGate Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended (Filed With SEC on August 3, 2018)
- Form of Warrant (Filed With SEC on April 13, 2018)
- Form of Securities Purchase Agreement (Filed With SEC on April 13, 2018)
- Form of Warrant (Filed With SEC on April 9, 2018)
- Engagement Letter, dated as March 15, 2018, by and between the Registrant and H.C. Wainwright & Co., LLC (Filed With SEC on April 9, 2018)
- Form of Securities Purchase Agreement (Filed With SEC on April 9, 2018)
- Offer Letter between the Company and Sarah Romano, dated as of January 1, 2018 (Filed With SEC on January 4, 2018)
- EyeGate Pharmaceuticals, Inc. Change in Control Severance Plan (Filed With SEC on November 29, 2017)
- Third Amended and Restated Employment Agreement by and between EyeGate Pharmaceuticals, Inc. and Stephen From, dated as of November 29, 2017 (Filed With SEC on November 29, 2017)
- COMMON STOCK PURCHASE WARRANT EYEGATE PHARMACEUTICALS, INC. (Filed With SEC on June 9, 2017)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 9, 2017)
- COMMON STOCK PURCHASE WARRANT EYEGATE PHARMACEUTICALS, INC. (Filed With SEC on June 5, 2017)
- 430 Park Avenue | New York, New York 10022| 212 ###-###-#### Security services provided by H.C. Wainwright& Co., LLC | Member: FINRA/SIPC (Filed With SEC on June 5, 2017)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 5, 2017)
- LICENSE AGREEMENT (Filed With SEC on February 23, 2017)
- 271 Waverly Oaks Road, Suite 108 Waltham, MA 02452 (Filed With SEC on February 6, 2017)
- COMMON STOCK PURCHASE WARRANT EYEGATE PHARMACEUTICALS, INC. (Filed With SEC on June 27, 2016)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 27, 2016)
- 430 Park Avenue | New York, New York 10022| 212 ###-###-#### Security services provided by H.C. Wainwright& Co., LLC | Member: FINRA/SIPC (Filed With SEC on June 27, 2016)
- AT THE MARKET OFFERING AGREEMENT May 24, 2016 (Filed With SEC on May 25, 2016)
- 271 Waverly Oaks Road, Suite 108 Waltham, MA 02452 (Filed With SEC on April 29, 2016)
- EYEGATE PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED EMPLOYMENTAGREEMENT (Filed With SEC on March 30, 2016)
- STOCK PURCHASE AGREEMENT among EYEGATE PHARMACEUTICALS,INC. and THE STOCKHOLDERS OF JADETHERAPEUTICS, INC. dated as of March 7, 2016 (Filed With SEC on March 7, 2016)
- UNDERWRITING AGREEMENT between EYEGATE PHARMACEUTICALS, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters (Filed With SEC on August 5, 2015)
- EYEGATE PHARMACEUTICALS, INC. WARRANT AGENCY AGREEMENT (Filed With SEC on August 5, 2015)
- UNDERWRITING AGREEMENT between EYEGATE PHARMACEUTICALS, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters (Filed With SEC on July 30, 2015)
- EYEGATE PHARMACEUTICALS, INC. FORM OF WARRANT AGENCY AGREEMENT (Filed With SEC on July 30, 2015)
- UNDERWRITING AGREEMENT between EYEGATE PHARMACEUTICALS, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters (Filed With SEC on July 15, 2015)
- LICENSE AGREEMENT (Filed With SEC on July 10, 2015)
- EYEGATEPHARMACEUTICALS, INC. Amendment to Amended and RestatedEmployment Agreement (Filed With SEC on May 15, 2015)
- UNDERWRITING AGREEMENT between EYEGATE PHARMACEUTICALS, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters (Filed With SEC on February 4, 2015)
- Form of Underwriters’ Warrant Agreement (Filed With SEC on February 4, 2015)
- UNDERWRITINGAGREEMENT between EYEGATEPHARMACEUTICALS, INC. and AEGISCAPITAL CORP., asRepresentative of the Several Underwriters (Filed With SEC on December 24, 2014)
- Form of Underwriters’ Warrant Agreement (Filed With SEC on December 24, 2014)
- EYEGATE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN (Filed With SEC on December 24, 2014)
- EYEGATE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN (Filed With SEC on September 12, 2014)
- EyegatePharmaceuticals, Inc. EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on September 12, 2014)
- UNDERWRITING AGREEMENT between EYEGATE PHARMACEUTICALS, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters (Filed With SEC on August 29, 2014)
- Form of Representative’s WarrantAgreement (Filed With SEC on August 29, 2014)
- Eyegatepharmaceuticals, InC. 2005EQUITY INCENTIVE PLAN (Filed With SEC on July 30, 2014)
- EYEGATE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN (Filed With SEC on July 30, 2014)
- EyegatePharmaceuticals, Inc. EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on July 30, 2014)
- Hereinafter known as the “OPTIS GROUP” (Filed With SEC on July 30, 2014)
- Amended and Restated License Agreement (Filed With SEC on July 30, 2014)
- INDEMNIFICATIONAGREEMENT (Filed With SEC on July 30, 2014)
- EYEGATE PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED EMPLOYMENTAGREEMENT (Filed With SEC on July 30, 2014)
- EYEGATE PHARMACEUTICALS, INC. 271 Waverley Oaks Road Suite 108 Waltham, MA 02452 (Filed With SEC on July 30, 2014)
- EYEGATE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT (Filed With SEC on July 30, 2014)
- EYEGATE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN NOTICE OF STOCK UNIT AWARD (Filed With SEC on July 30, 2014)
- FIRST AMENDMENT TO FIRST AMENDED ANDRESTATED LICENSE AGREEMENT (Filed With SEC on July 30, 2014)